Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients

Mijke Buitinga, Tom Jansen, Inge van der Kroon, Wietske Woliner-van der Weg, Marti Boss, Marcel Janssen, Erik Aarntzen, Martin Béhé, Damian Wild, Eric Visser, Maarten Brom and Martin Gotthardt
Journal of Nuclear Medicine June 2019, 60 (6) 812-816; DOI: https://doi.org/10.2967/jnumed.118.219980
Mijke Buitinga
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Jansen
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inge van der Kroon
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wietske Woliner-van der Weg
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marti Boss
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel Janssen
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Aarntzen
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Béhé
2Center for Radiopharmaceutical Sciences, ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damian Wild
3Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Visser
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten Brom
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Gotthardt
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Time line of crossover trial.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Quantitative analysis of kidney and pancreatic uptake of 111In-labeled exendin-4 in SPECT/CT scans. SPECT/CT images (A, B, D, and E) were obtained 24 h after 111In-exendin injection, coinfused with saline (A and B) or Gelofusine (D and E). In 3 of 10 patients, 3-dimensional projections of SPECT images (C and F) demonstrated that pancreas could be more clearly discriminated from kidney signal after Gelofusine injection (arrows) (F). Kidney uptake of 111In-labeled exendin-4 was significantly reduced after administration of Gelofusine (G), whereas activity concentration in pancreas remained same (H). Clearance of 111In-labeled exendin-4 was determined in urine (I) and in blood (J). *P < 0.05. **P < 0.01. ID = injected dose.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Dosimetry Calculations for 177Lu-Labeled Exendin

    ParameterLow kidney uptakeHigh kidney uptake
    Patient 1Patient 2Patient 3Patient 4Patient 5Patient 1Patient 2Patient 3Patient 4Patient 5
    MFMFMFMFMFMFMFMFMFMF
    TIAC insulinoma (h)0.440.440.810.810.650.650.620.620.960.960.440.440.810.810.650.650.620.620.960.96
    Kidney dose (Gy)2323232323232323232323232323232323232323
    Without Gelofusine
     Max. inj. activity (GBq)1.791.641.791.641.791.641.791.641.791.641.121.041.121.041.121.041.121.041.121.04
     Insulinoma dose (Gy)127.8117.454.248.09082.778.572.2112.2103.180.274.132.930.356.552.249.345.570.765.1
     Islet dose (Gy)4.04.84.04.84.04.84.04.84.04.82.63.02.63.02.63.02.63.02.63.0
    With Gelofusine
     Max. inj. activity (GBq)2.182.012.182.012.182.012.182.012.182.011.381.261.381.261.381.261.381.261.381.26
     Insulinoma dose (Gy)156.1143.663.858.7109.9101.195.988.2137.0126.098.590.240.236.969.363.560.555.486.479.2
     Islet dose (Gy)4.95.84.95.84.95.84.95.84.95.83.13.73.13.73.13.73.13.73.13.7
    • Max. inj. = maximum injected.

    • Input parameters for model: islet size, 400 μm; percentage of islets in pancreas, 2%.

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 60 (6)
Journal of Nuclear Medicine
Vol. 60, Issue 6
June 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients
Mijke Buitinga, Tom Jansen, Inge van der Kroon, Wietske Woliner-van der Weg, Marti Boss, Marcel Janssen, Erik Aarntzen, Martin Béhé, Damian Wild, Eric Visser, Maarten Brom, Martin Gotthardt
Journal of Nuclear Medicine Jun 2019, 60 (6) 812-816; DOI: 10.2967/jnumed.118.219980

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients
Mijke Buitinga, Tom Jansen, Inge van der Kroon, Wietske Woliner-van der Weg, Marti Boss, Marcel Janssen, Erik Aarntzen, Martin Béhé, Damian Wild, Eric Visser, Maarten Brom, Martin Gotthardt
Journal of Nuclear Medicine Jun 2019, 60 (6) 812-816; DOI: 10.2967/jnumed.118.219980
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Theranostics

  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
  • 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Show more Theranostics

Translational

  • [99mTc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study
  • Imaging Diverse Pathogenic Bacteria In Vivo with 18F-Fluoromannitol PET
  • Modeling Early Radiation DNA Damage Occurring During 177Lu-DOTATATE Radionuclide Therapy
Show more Translational

Similar Articles

Keywords

  • exendin-4
  • kidney uptake
  • insulinoma
  • radionuclide therapy
  • dosimetry
SNMMI

© 2025 SNMMI

Powered by HighWire